quinacrine has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaidya, B | 2 |
| Kulkarni, NS | 2 |
| Shukla, SK | 1 |
| Parvathaneni, V | 1 |
| Chauhan, G | 1 |
| Damon, JK | 1 |
| Sarode, A | 1 |
| Garcia, JV | 1 |
| Kunda, N | 1 |
| Mitragotri, S | 1 |
| Gupta, V | 2 |
| Bhateja, P | 1 |
| Dowlati, A | 2 |
| Sharma, N | 2 |
| Dermawan, JK | 1 |
| Gurova, K | 1 |
| Pink, J | 1 |
| De, S | 1 |
| Narla, G | 1 |
| Stark, GR | 1 |
| Li, XT | 1 |
| Zhou, ZY | 1 |
| Jiang, Y | 1 |
| He, ML | 1 |
| Jia, LQ | 1 |
| Zhao, L | 1 |
| Cheng, L | 1 |
| Jia, TZ | 1 |
1 trial available for quinacrine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2018 |
4 other studies available for quinacrine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics.
Topics: Administration, Inhalation; Aerosols; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle | 2020 |
Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Q | 2021 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tu | 2014 |
PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2015 |